Genmab (GMAB) says its projected revenue growth for 2025 is driven by higher royalties, net product sales and collaboration revenue.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment
- Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment
- Genmab’s Phase 3 Study on Rina-S: A Potential Game-Changer for Ovarian Cancer Treatment
- Genmab’s GEN1057 Trial: A New Hope in Cancer Treatment?
- Pfizer and Genmab’s Tivdak Study: Ocular Side Effects Under the Microscope